Ensifentrine FDA Approval Status
FDA Approved: No
Generic name: ensifentrine
Company: Verona Pharma plc
Treatment for: COPD, Maintenance
Ensifentrine is a selective dual inhibitor of the enzymes phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) in development for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
- COPD refers to a group of diseases that cause airflow blockage and breathing-related problems. It includes emphysema and chronic bronchitis.
- Ensifentrine works in the treatment of COPD through combined bronchodilator and non-steroidal anti-inflammatory actions.
Development timeline for ensifentrine
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
